T1	Participants 52 69	autistic disorder
T2	Participants 421 736	ndividuals with a DSM-IV diagnosis of autistic disorder (mean age, 16.3 years; range, 10-36 years) were randomly assigned, by using a Latin square design, to the following 7-week trials: placebo, clomipramine (mean daily dose, 128.4 mg; range, 100-150 mg), or haloperidol (mean daily dose, 1.3 mg; range, 1-1.5 mg).
T3	Participants 199 218	treatment of autism
T4	Participants 745 822	36 subjects were analyzed and taken together; the results favored haloperidol
